• Advanced ovarian cancer:
    • 1st line treatment:
      • IV 175mg/m² over 3 hours every 3 weeks (follow with cisplatin) OR 135mg/m² over 24 hours every 3 weeks (follow with cisplatin)
    • Previously treated:
      • IV 135-175mg/m² over 3 hours every 3 weeks
  • Breast cancer:
    • Node positive (adjuvant chemotherapy):
      • IV 175mg/m² IV over 3 hours every 3 weeks *4 cycles (with doxorubicin-containing regimen)
    • Metastatic disease (failure of initial chemotherapy or relapse within 6 months following adjuvant chemotherapy):
      • IV 175mg/m² over 3 hours every 3 weeks
  • Non-small cell lung cancer:
    • IV 135mg/m² over 24 hours every 3 weeks (follow with cisplatin/carboplatin)
  • AIDS-related Kaposi’s Sarcoma (2nd-line treatment):
    • IV 135 g/m² over 3 hours every 3 weeks OR 100mg/m² over 3 hours every 2 weeks

Injection: 6mg/mL

  • Administer taxane derivatives before platinum derivatives (cisplatin, carboplatin) in sequential infusions to limit myelosuppression and to enhance efficacy
  • Administer corticosteroids, H1-antagonists, H2 antagonists prior to paclitaxel administration to minimize potential for anaphylaxis
  • Non-PVC tubing should be used to minimize leaching

Taxane anticancer

It promotes formation and inhibits disassembly of stable microtubules, inhibiting mitosis

  • Neutropenia
  • Leukopenia
  • Alopecia
  • Anemia
  • Peripheral neuropathy
  • Arthralgia
  • Myalgia
  • Nausea
  • Vomiting
  • Hypersensitivity reaction
  • Diarrhea
  • Mucositis
  • Infection
  • Abnormal ECG
  • Elevated alkaline phosp
  • Elevated ALT/AST
  • Thrombocytopenia
  • Asthenia
  • Injection site reaction
  • Fever
  • Hypotension
  • Bleeding
  • Elevated bilirubin
  • Elevated creatine
  • Bradycardia
  • Edema
  • Hypersensitivity to components
  • Hypersensitivity to castor oil
  • Pregnancy 1st trimester
  • ANC <1500 (solid tumor use)
  • ANC <1000 (patients with AIDS-associated Kaposi sarcoma)
  • Breastfeeding during treatment and for at least 6-10 days after discontinuation

WARNING:

  • Anaphylaxis/severe hypersensitivity reaction: Pretreat all patients with corticosteroids, diphenhydramine and H2 antagonists; fatal reactions have occurred despite premeds
  • Live vaccines

                          Drug Status

Availability Prescription only
Pregnancy Category D
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Cansure 100mg/16.7mL Injection 1’s PSM Pharma PSM Pharma
Cansure 260mg/43.4mL Injection 1’s PSM Pharma PSM Pharma
Celtax 100mg Injection 1’s Celon Labs Europa Healthcare
Celtax 300mg Injection 1’s Celon Labs Europa Healthcare
Intaxel 30mg/5mL Injection 1’s Fresenius Kabi Nairobi Enterprises
Intaxel 100mg/17mL Injection 1’s Fresenius Kabi Nairobi Enterprises
Intaxel 200mg/43.4mL Injection 1’s Fresenius Kabi Nairobi Enterprises
Intaxel 300mg/50mL Injection 1’s Fresenius Kabi Nairobi Enterprises
Naprotax 260mg/43.34mL Injection 1’s Miracalus Ripple Pharma
Naprotax 100mg/16.67mL Injection 1’s Miracalus Ripple Pharma
Otel 30mg/5mL Injection 1’s Glenmark Pharma Glenmark Pharma
Otel 100mg/16.7mL Injection 1’s Glenmark Pharma Glenmark Pharma
Pacix 100mg/16.7mL Injection 1’s Emcure Pharma Lazor Pharma
Pacix 30mg/5mL Injection 1’s Emcure Pharma Lazor Pharma
Paclicord 100mg/ 16.7ml Injection 1’s Intas Pharma Accord Healthcare
Paclicord 300mg/ 50mL Injection 1’s Intas Pharma Accord Healthcare
Paclitero 100mg; 300mg Injection 1’s Hetero Labs Unisel Ltd
Pacliwell 6mg/mL Injection 1’s Getwell Pharma Nairobi Enterprises
Pacliwell 30mg/5mL Injection 1’s Getwell Pharma Nairobi Enterprises
Pacliwell 100mg/17mL Injection 1’s Getwell Pharma Nairobi Enterprises
Pacliwell 260mg/43.4mL Injection 1’s Getwell Pharma Nairobi Enterprises
Paxol 30mg/5mL Injection 1’s Venus Remedies Surgipharm Ltd
Paxol 100mg/ 16.7ml Injection 1’s Venus Remedies Surgipharm Ltd
Petaxel 30mg/5mL Injection 1’s Zydus Healthcare Sai Pharma
Petaxel 100mg/16.7mL Injection 1’s Zydus Healthcare Sai Pharma